Romiplostim for the treatment of chronic immune thrombocytopenia

Review Decision: May 2014 information

Appendix A: GE decision paper - May 2014 (PDF 168 KB)

Review Proposal: March 2014 information

Appendix A: provisional matrix of stakeholders (PDF 37 KB)

Appendix B: GE proposal paper - March 2014 (PDF 384 KB)

TA221 Thrombocytopenic purpura - romiplostim: press release information

2011/072 NICE recommends romiplostim for the treatment of rare blood disorder (PDF 69 KB)

Thrombocytopenic purpura - romiplostim: EIA (PDF 16 KB)

Thrombocytopenic purpura - romiplostim: final appraisal determination information

Thrombocytopenic purpura - romiplostim: final appraisal determination (PDF 252 KB)

Thrombocytopenic purpura - romiplostim: response to consultee, commentator and public comments on the appraisal consultation document (ACD) 2 (PDF 247 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from Amgen (PDF 167 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the ITP Support Association (PDF 58 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Royal College of Nursing (PDF 59 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Royal College of Pathologists and British Society for Haematology (PDF 211 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Department of Health (PDF 68 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from GlasxoSmithKline (PDF 209 KB)

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received via the NICE website (PDF 95 KB)

Thrombocytopenic purpura - romiplostim: second appraisal consultation

Thrombocytopenic purpura - romiplostim: appraisal consultation document information

Thrombocytopenic purpura - romiplostim: comments on the Patient Access Scheme submission

Thrombocytopenic purpura - romiplostim: comments on the Patient Access Scheme submisson prepared by the Aberdeen HTA Group (PDF 222 KB)

Thrombocytopenic purpura - romiplostim: addendum to the coments on the Patient Access Scheme, and responses to the ERG report and Appraisal committee document produced by the ERG (PDF 357 KB)

Thrombocytopenic purpura - romiplostim: comments on the first Appraisal Consultation Document, ERG report and Patient Access Scheme submission from the manufacturer (Amgen)

Thrombocytopenic purpura - romiplostim: Amgen Patient Access Scheme submission (PDF 862 KB)

Thrombocytopenic purpura - romiplostim: letter to NICE regarding forthcoming changes to the romiplostim summary of product characteristics (SPC) (PDF 30 KB)

Thrombocytopenic purpura - romiplostim: response to the ACD (PDF 293 KB)

Thrombocytopenic purpura - romiplostim: response to the ERG report (PDF 124 KB)

Thrombocytopenic purpura - romiplostim: non-manufacturer submissions

Thrombocytopenic purpura - romiplostim: submission from the British Committee for Standards in Haematology (BCSH) (PDF 121 KB)

Thrombocytopenic purpura - romiplostim: submission from the Department of Health (PDF 29 KB)

Thrombocytopenic purpura - romiplostim: submission from GlaxoSmithKline (PDF 15 KB)

Thrombocytopenic purpura - romiplostim: submission from the ITP Support Association (PDF 26 KB)

Thrombocytopenic purpura - romiplostim: submission from the Royal College of Nursing (PDF 32 KB)

Thrombocytopenic purpura - romiplostim: submission from the Royal College of Pathologists and BSH (PDF 86 KB)

Thrombocytopenic purpura - romiplostim: submission from the Welsh Assembly Government (PDF 30 KB)

Thrombocytopenic purpura - romiplostim: expert personal statement - Wimperis (PDF 33 KB)

Thrombocytopenic purpura - romiplostim: comments received through the website (PDF 104 KB)

Thrombocytopenic purpura - romiplostim: press release information

2010/170 NICE recommends romiplostim for the treatment of chronic idiopathic thrombocytopenic purpura (ITP) (PDF 37 KB)

Thrombocytopenic purpura - romiplostim: update to consultees and commentators regarding rescheduling of 3rd committee meeting (PDF 21 KB)

Thrombocytopenic purpura - romiplostim: update to consultees and commentators regarding 3rd committee meeting (PDF 21 KB)

Thrombocytopenic purpura - romiplostim: update to consultees and commentators regarding timelines (PDF 10 KB)

Thrombocytopenic purpura - romiplostim: appraisal consultation

Thrombocytopenic purpura - romiplostim: appraisal consultation document information

Evaluation report

Pre-meeting briefing (PDF 126 KB)

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP): A Single Technology Appraisal (PDF 763 KB)

Non-manufacturer submissions

ITP Support Association (PDF 43 KB)

Royal College of Nursing (PDF 30 KB)

Manufacturer's submission (PDF 1.07 MB)

Expert written personal statements

Atkinson (Mrs Atkinson was unable to attend the meeting due to transport difficulties) (PDF 55 KB)

Bolton-Maggs (PDF 33 KB)

Elston (PDF 43 KB)

Grainger (PDF 16 KB)

Watson (PDF 17 KB)

Wimperis (PDF 14 KB)

Thrombocytopenic purpura - romiplostim: update to consultees and commentators following launch of romiplostim (PDF 21 KB)

Thrombocytopenic purpura - romiplostim: update to stakeholders (PDF 24 KB)

Thrombocytopenic purpura - romiplostim: letter to consultees and commentators about the February meeting. (PDF 12 KB)

Thrombocytopenic purpura - romiplostim: final scope (PDF 29 KB)

Thrombocytopenic purpura - romiplostim: final matrix of consultees and commentators (PDF 45 KB)

Thrombocytopenic purpura - romiplostim: response to comments on the draft scope (PDF 65 KB)

Thrombocytopenic purpura - romiplostim: response to comments on the provisional matrix (PDF 25 KB)

Thrombocytopenic purpura - romiplostim: draft scope (PDF 30 KB)

Thrombocytopenic purpura - romiplostim: provisional matrix (PDF 42 KB)